Cipla Sees Changed Profile; Wraps Up Europe Revamp
Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.
You may also be interested in...
Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.
The rumor mill has it that Cipla has begun a significant personnel "rightsizing" effort as it tweaks its business strategy for the next phase of growth. The Indian firm maintains that any job cuts are from natural attrition from its evolving business model in Europe.
Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.